A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients
Core Binding Factor (CBF)-AML is one of the most common somatic mutations in acute myeloid leukemia (AML). t(8;21)/AML1-ETO-positive acute myeloid leukemia accounts for 5-10% of all AMLs. In this study, we consecutively included 254 AML1-ETO patients diagnosed and treated at our institute from Decem...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.783114/full |
| _version_ | 1798026018236137472 |
|---|---|
| author | Min Yang Min Yang Min Yang Bide Zhao Jinghan Wang Jinghan Wang Jinghan Wang Yi Zhang Yi Zhang Yi Zhang Chao Hu Chao Hu Chao Hu Lixia Liu Jiayue Qin Feng Lou Shanbo Cao Chengcheng Wang Wenjuan Yu Wenjuan Yu Wenjuan Yu Hongyan Tong Hongyan Tong Hongyan Tong Haitao Meng Haitao Meng Haitao Meng Jian Huang Jian Huang Jian Huang Honghu Zhu Honghu Zhu Honghu Zhu Jie Jin Jie Jin Jie Jin |
| author_facet | Min Yang Min Yang Min Yang Bide Zhao Jinghan Wang Jinghan Wang Jinghan Wang Yi Zhang Yi Zhang Yi Zhang Chao Hu Chao Hu Chao Hu Lixia Liu Jiayue Qin Feng Lou Shanbo Cao Chengcheng Wang Wenjuan Yu Wenjuan Yu Wenjuan Yu Hongyan Tong Hongyan Tong Hongyan Tong Haitao Meng Haitao Meng Haitao Meng Jian Huang Jian Huang Jian Huang Honghu Zhu Honghu Zhu Honghu Zhu Jie Jin Jie Jin Jie Jin |
| author_sort | Min Yang |
| collection | DOAJ |
| description | Core Binding Factor (CBF)-AML is one of the most common somatic mutations in acute myeloid leukemia (AML). t(8;21)/AML1-ETO-positive acute myeloid leukemia accounts for 5-10% of all AMLs. In this study, we consecutively included 254 AML1-ETO patients diagnosed and treated at our institute from December 2009 to March 2020, and evaluated molecular mutations by 185-gene NGS platform to explore genetic co-occurrences with clinical outcomes. Our results showed that high KIT VAF(≥15%) correlated with shortened overall survival compared to other cases with no KIT mutation (3-year OS rate 26.6% vs 59.0% vs 69.6%, HR 1.50, 95%CI 0.78-2.89, P=0.0005). However, no difference was found in patients’ OS whether they have KIT mutation in two or three sites. Additionally, we constructed a risk model by combining clinical and molecular factors; this model was validated in other independent cohorts. In summary, our study showed that c-kit other than any other mutations would influence the OS in AML1-ETO patients. A proposed predictor combining both clinical and genetic factors is applicable to prognostic prediction in AML1-ETO patients. |
| first_indexed | 2024-04-11T18:29:34Z |
| format | Article |
| id | doaj.art-28dfeabbc52046bc90d69b587a7c6651 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T18:29:34Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-28dfeabbc52046bc90d69b587a7c66512022-12-22T04:09:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.783114783114A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia PatientsMin Yang0Min Yang1Min Yang2Bide Zhao3Jinghan Wang4Jinghan Wang5Jinghan Wang6Yi Zhang7Yi Zhang8Yi Zhang9Chao Hu10Chao Hu11Chao Hu12Lixia Liu13Jiayue Qin14Feng Lou15Shanbo Cao16Chengcheng Wang17Wenjuan Yu18Wenjuan Yu19Wenjuan Yu20Hongyan Tong21Hongyan Tong22Hongyan Tong23Haitao Meng24Haitao Meng25Haitao Meng26Jian Huang27Jian Huang28Jian Huang29Honghu Zhu30Honghu Zhu31Honghu Zhu32Jie Jin33Jie Jin34Jie Jin35Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaAcornmed Biotechnology Co., Ltd., Beijing, ChinaAcornmed Biotechnology Co., Ltd., Beijing, ChinaAcornmed Biotechnology Co., Ltd., Beijing, ChinaAcornmed Biotechnology Co., Ltd., Beijing, ChinaAcornmed Biotechnology Co., Ltd., Beijing, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, ChinaCore Binding Factor (CBF)-AML is one of the most common somatic mutations in acute myeloid leukemia (AML). t(8;21)/AML1-ETO-positive acute myeloid leukemia accounts for 5-10% of all AMLs. In this study, we consecutively included 254 AML1-ETO patients diagnosed and treated at our institute from December 2009 to March 2020, and evaluated molecular mutations by 185-gene NGS platform to explore genetic co-occurrences with clinical outcomes. Our results showed that high KIT VAF(≥15%) correlated with shortened overall survival compared to other cases with no KIT mutation (3-year OS rate 26.6% vs 59.0% vs 69.6%, HR 1.50, 95%CI 0.78-2.89, P=0.0005). However, no difference was found in patients’ OS whether they have KIT mutation in two or three sites. Additionally, we constructed a risk model by combining clinical and molecular factors; this model was validated in other independent cohorts. In summary, our study showed that c-kit other than any other mutations would influence the OS in AML1-ETO patients. A proposed predictor combining both clinical and genetic factors is applicable to prognostic prediction in AML1-ETO patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.783114/fullacute myeloid leukemiaAML-ETOnext-generation sequencingprognosisLASSO Cox regression |
| spellingShingle | Min Yang Min Yang Min Yang Bide Zhao Jinghan Wang Jinghan Wang Jinghan Wang Yi Zhang Yi Zhang Yi Zhang Chao Hu Chao Hu Chao Hu Lixia Liu Jiayue Qin Feng Lou Shanbo Cao Chengcheng Wang Wenjuan Yu Wenjuan Yu Wenjuan Yu Hongyan Tong Hongyan Tong Hongyan Tong Haitao Meng Haitao Meng Haitao Meng Jian Huang Jian Huang Jian Huang Honghu Zhu Honghu Zhu Honghu Zhu Jie Jin Jie Jin Jie Jin A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients Frontiers in Oncology acute myeloid leukemia AML-ETO next-generation sequencing prognosis LASSO Cox regression |
| title | A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients |
| title_full | A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients |
| title_fullStr | A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients |
| title_full_unstemmed | A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients |
| title_short | A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients |
| title_sort | predictor combining clinical and genetic factors for aml1 eto leukemia patients |
| topic | acute myeloid leukemia AML-ETO next-generation sequencing prognosis LASSO Cox regression |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.783114/full |
| work_keys_str_mv | AT minyang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT minyang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT minyang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT bidezhao apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jinghanwang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jinghanwang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jinghanwang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT yizhang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT yizhang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT yizhang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chaohu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chaohu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chaohu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT lixialiu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiayueqin apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT fenglou apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT shanbocao apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chengchengwang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT wenjuanyu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT wenjuanyu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT wenjuanyu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT hongyantong apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT hongyantong apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT hongyantong apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT haitaomeng apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT haitaomeng apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT haitaomeng apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jianhuang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jianhuang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jianhuang apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT honghuzhu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT honghuzhu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT honghuzhu apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiejin apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiejin apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiejin apredictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT minyang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT minyang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT minyang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT bidezhao predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jinghanwang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jinghanwang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jinghanwang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT yizhang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT yizhang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT yizhang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chaohu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chaohu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chaohu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT lixialiu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiayueqin predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT fenglou predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT shanbocao predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT chengchengwang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT wenjuanyu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT wenjuanyu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT wenjuanyu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT hongyantong predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT hongyantong predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT hongyantong predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT haitaomeng predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT haitaomeng predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT haitaomeng predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jianhuang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jianhuang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jianhuang predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT honghuzhu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT honghuzhu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT honghuzhu predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiejin predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiejin predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients AT jiejin predictorcombiningclinicalandgeneticfactorsforaml1etoleukemiapatients |